Salt Lake City, Utah –Second Heart Assist, Inc., a clinical stage medical device company, today announced completion of a $4.41 million Series H financing led by Vestech Securities LLC. This brings total paid in cash capital to over $15.4 million.
Second Heart Assist, Inc. will use new funding to continue to advance testing of both its 1st generation Whisper TM catheter based circulatory assist pump and Freedom TM its 2nd generation wireless powered implant. Both products are based on the company’s patented aortic stent platform technology.
The company is about to embark on a second round of clinical studies this time in treating patients with cardio-renal syndrome heart failure. Details of this new OUS study will be announced shortly.
December 24th, 2022 the company received a Letter of Allowance from the United States Patent and Trademark office on the issuance of 21 new patent claims. These newly issued patent claims add to over 100 previous patent claims that company has had issued or exclusively licensed. The company believes it has the pre-eminent IP estate in the sector especially when it comes to a stable wireless powered implant that also maintains aortic wall pulsatility.
“The Second Heart Assist, Inc. device pipeline is poised to provide valuable new tools to physicians managing patients in cardio-renal syndrome and heart failure. These patients are a great challenge especially when diuretic resistant. New tools are certainly needed to provide better management.” said Dr. Leslie Miller, M.D Chief Medical Officer.
“The entire Second Heart team is highly focused on completing our planned cardio-renal syndrome heart failure pilot study in North America and preparing for a subsequent pivotal Phase II multi-center study including full cGMP compliance in manufacturing. This new funding should permit us to reach these goals in 2023.” stated jointly Howard J. Leonhardt, Executive Chairman & CEO and Jeff Donofrio President
About Second Heart Assist, Inc.:
Incorporated in 2017 Second Heart Assist, Inc. is focused on developing a pipeline of next generation percutaneous (non surgical) placed circulatory assist devices. See www.secondheartinc.com for more information. The Second Heart development project began within the Leonhardt’s Launchpads innovation and startup launch accelerator program.
Howard J. Leonhardt
Executive Chairman & CEO